close
BRIEFING ON CART-T CELLS TRIALS

BRIEFING ON CART-T CELLS TRIALS

 

BioPharmAnalyses is happy to announce the release of the first issue of its
“BRIEFING ON CART-T CELLS TRIALS”

CAR-T cells therapies are at the forefront of innovation in oncology
“BRIEFING ON CART-T CELLS TRIALS” provides you
with an accurate overview to explore the latest trials
in this hot and rapidly evolging field.

More than 20 diseases, mainly hematological cancers and solid tumors

47 trials and 33 sponsors in Asia, Europa and USA

More than 12 antigens targeted by clinical trials

registered on Clinicaltrials.gov from 01/01/2017 to 01/10/2018

BREAKDOWN BY DISEASE

Acute Lymphoblastic Leukemia (ALL), B Acute Lymphoblastic Leukemia (B – ALL),  Acute Myeloid Leukemia, B-cell Lymphoma, Diffuse Large B-cell Lymphoma, Blastic Plasmacytoid Dendritic Cell Neoplasm,  Chronic Lymphocytic Leukemia (CLL,) Colon Cancer Liver Metastasis,  EGFR-positive Colorectal Cance,r Hematological Malignancies, Leukemias, Lymphomas Hepatocellular Carcinoma,  Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma Lymphoid Cancer,  Multiple Myeloma ,Non Hodgkin Lymphoma,  Pancreatic Cancer,  Plasma Cell Myeloma, Solid Tumors,  Systemic Lupus Erythematosus (SLE)

To get the full report: Subscription Form

To get an Example of technical datasheet

DIFFUSE LARGE B CELL LYMPHOMA

Target: CD19/CD22 CD19/22 
CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma
ID: NCT03287817 – AUTO3-DB1 – ALEXANDER
Company: Autolus (UK)
Product: CAR T cell treatment targeting CD19 and CD22
Phase: I/II
Status: Recruiting
Start/Planned completion: SEP 2017/MAR 2021
Estimated Enrollment: 120
Sites: 3 (UK)
Updated: AUG 2018
Contact: clinicaltrials@autolus.com
Related Informations/Publications
*Discov Med. 2016 Oct;22(121):215-220.
Recent advances in engineered T cell therapies targeting B cell malignancies. Singh N. University of Pennsylvania, Philadelphia, PA 19104, USA
Results /comments : Researchers here review landmark and recent clinical trials, as well as pre-clinical work that demonstrates significant promise in propelling this field further in the coming years
LinkAbstract 
*JUN 2018. Autolus Announces Pricing of Initial Public Offering. Link: Press Release *APR 2018 : Autolus announces license agreement with UCL Business PLC for clinical-stage product candidate in development for the treatment of B-cell malignancies Results / Comments : Autolus has acquired global rights from UCL Business plc (UCLB), the technology-transfer company of University College London (UCL), to develop and commercialize a novel CD19 chimeric antigen receptor (CAR) T cell therapy
LinkPress Release 

 


COMMENTS ARE OFF THIS POST